BI 7446

BI 7446: sourced facts only. name: "This strategy led to the discovery of 2',3'-CDN 13 (BI 7446), which features unprecedented potency and activates all five STING variants in cellular assays." [PMID:37450324]; target: "This strategy led to the discovery of 2',3'-CDN 13 (BI 7446), which features unprecedented potency and activates all five STING variants in cellular assays." [PMID:37450324]; developer: "Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany." [PMID:37450324]; modality: "Novel cyclic dinucleotide (CDN)-based selective STING agonists were designed and synthesized comprising noncanonical nucleobase, ribose, and phosphorothioate moieties." [PMID:37450324]; stage: "Injection of low doses of CDN 13 into tumors in mice induced long-lasting, tumor-specific immune-mediated tumor rejection." [PMID:37450324]